Evidence map›Paper›PMID 41341028›Full record

ArticleFrontiers in pharmacology2025

Correction: Evaluating the efficacy of HRZE-based regimens in a high-burden murine model: a back-translational assessment of rifamycins and moxifloxacin substitutions in tuberculosis treatment.

Jason E Cummings, Lisa K Woolhiser, Vincent Guglielmi, Machenzie Wernsman, Ashley Romano, Samantha Pauly, John T Belisle, Nicholas D Walter, Gregory T Robertson, Richard A Slayden

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Jason E Cummings *Mycobacteria Research Laboratories, Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States.
Lisa K Woolhiser *Mycobacteria Research Laboratories, Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States.
Vincent GuglielmiMycobacteria Research Laboratories, Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States.
Machenzie WernsmanMycobacteria Research Laboratories, Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States.
Ashley RomanoMycobacteria Research Laboratories, Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States.
Samantha PaulyConsortium for Applied Microbial Metrics, Aurora, CO, United States.
John T BelisleMycobacteria Research Laboratories, Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States.
Nicholas D WalterConsortium for Applied Microbial Metrics, Aurora, CO, United States.
Gregory T RobertsonMycobacteria Research Laboratories, Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States.
Richard A SlaydenMycobacteria Research Laboratories, Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fphar.2025.1667592.].

Indexed as

drug discoveryhigh burdenhigh-burden aerosol BALB/c modelmycobacteriatuberculosis

Identifiers

PMID41341028
PMCPMC12670247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.